(Photo : Dr. Andrea Natale)
On August 5, 2020 a major breakthrough was made in the treatment of atrial fibrillation (AFib) that could change the future of how practitioners reduce one of the most prevalent causes of strokes. Nearly simultaneously, a new device called the WATCHMAN FLX
TM Left Atrial Appendage Closure was implanted into patients in Austin, Texas, and Thousand Oaks, California. The surgeries were led by Dr. Andrea Natale and Dr. Saibal Kar in California and Dr. Rodney Horton in Texas. This was the first FDA-approved implantation device for reducing strokes in patients with non-ventricular atrial fibrillation.
What Is Atrial Fibrillation?
BioSig Technologies Inc completes enrollment in PURE EP 2 0 clinical trial proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
First published on
While attention focused on iRhythm Technologies after Medicare rates for long-term cardiac monitoring were slashed in January, the fallout is now extending to other players and the future of the much-hyped market is being questioned.
Novitas Solutions, which sets regional Medicare rates as a Medicare Administrative Contractor, is working with iRhythm and rivals about possibly changing the published rates. However, there is no timetable for when or if the rates will change, leaving Wall Street and industry in a holding pattern.
Baird Equity Research analyst Mike Polark said that the reimbursement uncertainty makes any long-term growth expectation for iRhythm and the overall cardiac wearables market difficult.
Share it
While attention focused on iRhythm Technologies after Medicare rates for long-term cardiac monitoring were slashed in January, the fallout is now extending to other players and the future of the much-hyped market is being questioned.
Novitas Solutions, which sets regional Medicare rates as a Medicare Administrative Contractor, is working with iRhythm and rivals
about possibly changing the published rates. However, there is no timetable for when or if the rates will change, leaving Wall Street and industry in a holding pattern.
Baird Equity Research analyst Mike Polark said that the reimbursement uncertainty makes any long-term growth expectation for iRhythm and the overall cardiac wearables market difficult.